FLT3 agonists and secondary hematopoietic malignancies: a potential class effect

Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460

Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research